Sarcomatous transformation of an IDH-mutant oligodendroglioma matching to methylation class oligosarcoma despite vorasidenib use, a case report
Neuro-Oncology Advances · 12.01.2026 · 8 (1)
DOI: 10.1093/noajnl/vdag263 ↗Kurz gefasst
Fallbericht in der Zeitschrift Neuro-Oncology Advances, online erschienen am 23.10.2026. Verfasst von Lucy P Evans und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuropathology, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Sarcomatous transformation of diffuse gliomas is rare, particularly in IDH-mutant tumors. Oligosarcoma is a recently recognized methylation class of IDH-mutant, 1p/19q-codeleted gliomas with distinct histologic, molecular, and clinical features. We report a unique case of oligosarcoma arising from an IDH-mutant, 1p/19q-codeleted oligodendroglioma following documented disease progression and subsequent treatment with the IDH-inhibitor vorasidenib in the Investigating Vorasidenib in Glioma (INDIGO) trial. The recurrent tumor demonstrated spindle cell morphology, increased reticulin deposition, retained 1p/19q codeletion, and mutations in IDH1 p. R132H, TERT promoter, and TP53. DNA methylation profiling confirmed oligosarcoma. Following radiation and chemotherapy, a second recurrence demonstrated subclonal biallelic CDKN2A/B inactivation, consistent with continued clonal evolution. This case illustrates the molecular progression underlying sarcomatous transformation and highlights the importance of repeat tissue sampling and comprehensive molecular profiling in patients with atypical disease progression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Neuropathology, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington.
- Department of Neurosurgery and Neuroscience, The Permanente Medical Group, Redwood City, California.
- Department of Pathology, NYU Langone Medical Center, New York, New York.
- Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington.
- Department of Neurological Surgery, University of Washington, Seattle, Washington.
- Division of Molecular Pathology, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington.
ORCID-Profile: Lucy P Evans, Vyshak A Venur, Samuel N Emerson, Kristyn Galbraith
Förderung
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Evans, L. P., La, J., Snuderl, M., Venur, V. A., Emerson, S. N., & Galbraith, K. (2026). Sarcomatous transformation of an IDH-mutant oligodendroglioma matching to methylation class oligosarcoma despite vorasidenib use, a case report. Neuro-Oncology Advances, 8(1). https://doi.org/10.1093/noajnl/vdag263
Vancouver
Evans LP, La J, Snuderl M, Venur VA, Emerson SN, Galbraith K. Sarcomatous transformation of an IDH-mutant oligodendroglioma matching to methylation class oligosarcoma despite vorasidenib use, a case report. Neuro-Oncology Advances. 2026;8(1). doi:10.1093/noajnl/vdag263
BibTeX
@article{Evans2026,
author = {Evans, Lucy P and La, Janet and Snuderl, Matija and Venur, Vyshak A and Emerson, Samuel N and Galbraith, Kristyn},
title = {Sarcomatous transformation of an IDH-mutant oligodendroglioma matching to methylation class oligosarcoma despite vorasidenib use, a case report},
journal = {Neuro-Oncology Advances},
year = {2026},
volume = {8},
number = {1},
doi = {10.1093/noajnl/vdag263}
}
EUVIMED